Video

Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

It has previously been noted that men with testicular cancer have a slightly increased risk of developing intermediate- or high-risk prostate cancer, Siddiqui explains. No known biological mechanism is known. However, Siddiqui adds that in both prostate and testicular cancer, the hormonal axis is affected.

In this study, Siddiqui and his colleagues used a SEER database and created two cohorts: men with a history of testicular cancer, and a controlled population with melanoma. Melanoma was used, he explains, because it has a significant amount of survivors and has no known association with prostate cancer. After examining both cohorts, Siddiqui says there was an overall increase in prostate cancer in the testicular cancer arm vs the controlled population.

Intermediate- to high-risk prostate cancer was defined by a Gleason score of 7 or that greater than or equal to 8.

Additional subanalyses were conducted to identify other common risk factors such as age, radiation exposure, and race.

<<<

View more from the 2015 GU Cancer Symposium

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center